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Abstract
This review presents our current understanding of the pathophysi-
ology and potential treatment strategies with respect to mito-
chondrial disease in children. We focus on pathologies due to
mutations in nuclear DNA-encoded structural and assembly factors
of the mitochondrial oxidative phosphorylation (OXPHOS) system,
with a particular emphasis on isolated mitochondrial complex I
deficiency. Following a brief introduction into mitochondrial
disease and OXPHOS function, an overview is provided of the
diagnostic process in children with mitochondrial disorders. This
includes the impact of whole-exome sequencing and relevance of
cellular complementation studies. Next, we briefly present how
OXPHOS mutations can affect cellular parameters, primarily based
on studies in patient-derived fibroblasts, and how this information
can be used for the rational design of small-molecule treatment
strategies. Finally, we discuss clinical trial design and provide an
overview of small molecules that are currently being developed for
treatment of mitochondrial disease.
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Introduction
Mitochondria are semi-autonomous organelles that are present in
the cytosol of virtually all cells. They consist of a double-membrane
system that envelops the mitochondrial matrix compartment.
Functionally, mitochondria are key players in cellular ATP production,
fatty acid oxidation, heme biosynthesis, apoptosis induction, heat
generation, and calcium homeostasis. Mitochondrial diseases are an
expanding group of disorders of which the first signs and symptoms
can become apparent from prenatal development to late adulthood
(Koopman et al, 2012, 2013; Vafai & Mootha, 2012; Chinnery, 2015;
Lightowlers et al, 2015). These disorders can be defined as
“primary” (i.e., arising from a mutation in one of the genes encoding
a mitochondria-localized protein) or “secondary” (i.e., arising from
an external influence on mitochondria). The latter include off-target
effects of cholesterol-lowering statin drugs (e.g., Schirris et al, 2015)
and defects in the normal breakdown of branched-chain amino acids
as in propionic acidurias, which cause severe combined respiratory
chain deficiencies (e.g., Schwab et al, 2006). Here, we primarily
focus on mitochondrial diseases that (i) clinically manifest them-
selves before the age of 18 years and (ii) arise from mutations in
nuclear DNA (nDNA)-encoded structural proteins or assembly
factors of the mitochondrial oxidative phosphorylation (OXPHOS)
system. The mitochondrial OXPHOS system is embedded in the
mitochondrial inner membrane (MIM) and represents the final step
in the conversion of nutrients to energy by catalyzing the generation
of ATP (Fig 1A). This process is carried out by the combined action
of the mitochondrial electron transport chain (ETC) complexes
(Fig 1B) and the ATP-producing FoF1-ATPase (complex V; Fig 1C).
The ETC consists of four multiprotein complexes (complex I to
complex IV). Complex I and complex II abstract electrons from
reduced nicotinamide adenine dinucleotide (NADH) and reduced
flavin adenine dinucleotide (FADH2), respectively. Subsequently,
these electrons are donated to the electron carrier coenzyme Q10,
which transports them to complex III. From thereon, electrons are
transferred to the electron carrier cytochrome c and transported to
complex IV. At the latter complex, the electrons are donated to
molecular oxygen (O2) to form water. The energy released by the
electron transport is used to drive trans-MIM proton (H+) efflux
from the mitochondrial matrix by complexes I, III, and IV, thereby
creating an inward-directed proton-motive force (PMF). The latter
1 Department of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
2 Centre for Systems Biology and Bioenergetics, Radboud University Medical Center, Nijmegen, The Netherlands
3 Khondrion BV, Nijmegen, The Netherlands
4 Department of Pediatrics, Radboud Center for Mitochondrial Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
5 Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong
*Corresponding author. Tel: +31 24 3614430; E-mail: Jan.Smeitink@Radboudumc.nl
ª 2016 The Authors. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine Vol 8 | No 4 | 2016 311
Published online: March 7, 2016 
consists of a chemical (DpH) and an electrical component (Dw;
Fig 1C), and is used by complex V to generate ATP by chemiosmotic
coupling (Mitchell, 1961). In addition, DpH and/or Dw are essential
in sustaining virtually all other mitochondrial functions like the
import of pre-proteins from the cytosol and ion/metabolite exchange
(Fig 1C). In normal healthy cells (Fig 1A; red), cellular ATP is
predominantly generated through subsequent metabolic reactions of
the glycolysis pathway (cytosol), the pyruvate dehydrogenase
complex (PDHC, mitochondrial matrix), the tricarboxylic acid (TCA)
cycle (mitochondrial matrix), and the OXPHOS system (MIM). This
ATP is used to fuel energy-consuming cellular processes.
Diagnosing OXPHOS disease in children
The five complexes of the mitochondrial OXPHOS system are assem-
bled from 92 distinct proteins, requiring the assistance of at least 37
nDNA-encoded assembly factors (Nouws et al, 2012; Koopman et al,
2013). Each OXPHOS complex except complex II is of bi-genomic
origin and contains subunits encoded by mitochondrial DNA
(mtDNA) and nDNA (Koopman et al, 2013). Complex I is built up
from 44 subunits (7 mtDNA- and 37 nDNA-encoded), complex II of 4
subunits, complex III of 11 subunits (1 mtDNA, 10 nDNA), complex
IV of 14 subunits (3 mtDNA, 11 nDNA), and complex V of 19 sub-
units (2 mtDNA, 17 nDNA). As mentioned in the introduction, we
here primarily focus on mitochondrial diseases arising from muta-
tions in nDNA-encoded structural OXPHOS subunits and assembly
factors (Fig 2). Since the first description by Luft of a patient with
exercise intolerance and hyperthermia (Luft et al, 1962), the clinical
spectrum of diseases associated with OXPHOS malfunction has
tremendously broadened. In our opinion, a mitochondrial disease
should be considered in any patient presenting with an unexplained
mono- or multisystemic disease, whether progressive or not. Apply-
ing this relatively broad definition has important consequences for
the diagnostic approach in children, which is truly challenging given
the general lack of awareness within the broader medical commu-
nity, the relatively low incidence of mitochondrial disease, and the
complex genotype–phenotype relationship typical of these inborn
errors (Smeitink, 2003). It is also important to increase awareness
for mitochondrial disorders to shorten the potentially long delays
between appearance of the first symptoms and diagnostic analysis
and confirmation of the defect. Regarding the various clinical presen-
tations of mitochondrial OXPHOS disease, detailed reviews have
been presented elsewhere (Kisler et al, 2010; Koene & Smeitink,
2011; Lake et al, 2016). The majority of children suffering from mito-
chondrial OXPHOS disease lack a specific syndromic appearance and
some do not display increased blood lactate levels (Triepels et al,
1999). In case of neurodegenerative diseases, mutations in OXPHOS
subunits (mtDNA- or nDNA-encoded) and assembly factors have,
for instance, been associated with (Koopman et al, 2013): Leigh
(-like) syndrome, leukoencephalopathy, MELAS (mitochondrial
encephalomyopathy, lactic acidosis, and stroke-like episodes)
syndrome, NARP (neuropathy, ataxia, and retinitis pigmentosa),
Parkinsonism/MELAS, and (susceptibility) modification of PD
(Parkinson disease), and AD (Alzheimer’s disease).
The diagnostic process
When clinical signs and symptoms suggest a mitochondrial disor-
der, the following general strategy is carried out: (i) a detailed analy-
sis of the medical/family history to discriminate between maternal
(mtDNA) and Mendelian (nDNA) inheritance, (ii) evaluation of
mitochondrial biomarkers like lactate, pyruvate, alanine, fibroblast
growth factor 21 (FGF21; Suomalainen et al, 2011) and growth and
differentiation factor 15 in blood (GDF15; Yatsuga et al, 2015) or
Glossary
Blue Native-PAGE
A polyacrylamide gel-based electrophoresis technique that allows
separation of protein complexes in their native state. It is often used
for diagnostic and research purposes regarding the mitochondrial
oxidative phosphorylation system.
Complementation study
A test to study and confirm the pathogenicity of a mutation based on
a phenotypic screen. Often such a study is carried out by introducing
the wild-type gene in a patient (-derived) cell line and assessing the
reversal of the biological consequences of the mutated gene. The
latter could involve normalization of a depolarized mitochondrial
membrane potential, reversal of aberrant mitochondrial structure, or
restoration of an enzymatic deficiency.
Clinical trial
A crucial part of the drug development process consisting of 4 phases.
During a clinical trial (phase 1 to 3), the safety, pharmacokinetics,
pharmacodynamics, and effectiveness of a compound are assessed in
healthy volunteers and patient cohorts. Phase 4 consists of post-
market surveillance.
Leigh syndrome
A severe pediatric syndrome, first described by Dennis Leigh in 1951,
which is caused by either mutations in mitochondrial or nuclear DNA.
LHON
Leber’s hereditary optic neuropathy. A disorder that causes maternally
inherited blindness. LHON is frequently caused by mutations in subunits
of mitochondrial complex I, encoded by the mitochondrial DNA.
MELAS
Mitochondrial encephalomyopathy with lactic acidosis and stroke-like
episodes. A classical mitochondrial disorder primarily caused by the
m.3243A>G mutation in the mitochondrial DNA.
MRI
Magnetic resonance imaging, a non-invasive technique that uses
magnetic fields and radio waves to visualize different parts of the
human body. It is often applied during the diagnostic phase when a
mitochondrial disorder is suspected for analysis of anatomical and
physiological changes.
Outcome measures
Measures to the study the outcome of an intervention strategy such
as the effect of small-molecule treatment during a clinical trial.
Whole-exome sequencing
A technique that allows sequencing of all protein-coding genes within
the genome. The latter is known as the exome and constitutes only a
small part ( 1%) of the total genome.
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Figure 1. Glycolytic and mitochondrial ATP production, the electron transport chain, and oxidative phosphorylation.
(A) Glucose (Glc) and glutamine (Gln) enter the cell via dedicated transporters. In the cytosol, Glc is converted in the glycolysis pathway into pyruvate (Pyr), which is
transported to the mitochondrial matrix by the mitochondrial Pyr carrier (MPC). Alternatively, Pyr can be converted into lactate (Lac) by the action of lactate
dehydrogenase (LDH). Inside the mitochondrial matrix, Pyr is converted in to acetyl coenzyme A (acetyl-CoA; not shown) by pyruvate dehydrogenase (PDH) to enter the
tricarboxylic acid (TCA) cycle. The latter supplies the oxidative phosphorylation system (OXPHOS) with substrates in the form of reduced nicotinamide adenine
dinucleotide (NADH) and reduced flavin adenine dinucleotide (FADH2). In addition, Gln can enter the mitochondrial matrix where it is converted by glutaminase into
glutamate (not shown), a TCA cycle substrate. Also fatty acids can enter the mitochondrial matrix and enter the TCA cycle following their conversion into acetyl-CoA (not
shown). In healthy cells, the conversion of Glc into Pyr and its further metabolic conversion by the TCA and OXPHOS system constitute the major pathway for ATP
generation (marked in red). (B) The mitochondrial electron transport chain (ETC) consists of 4 multisubunit protein complexes (complex I to IV) that are embedded in the
mitochondrial inner membrane (MIM). Electrons are donated by NADH (at complex I) and FADH2 (at complex II) to coenzyme Q10 (Q), which transports them to complex
III. From thereon, electrons are transported to complex IV by cytochrome c (c) where they are donated to molecular oxygen (O2). Although not discussed here, in addition
to the ETC complexes also other proteins can provide coenzyme Q10 and cytochrome c with electrons (red boxes) in a tissue-dependent manner. During electron
transport, energy is liberated and used expel protons (H+) from the mitochondrial matrix intro the inter-membrane space (IMS) between the MIM and mitochondrial
outer membrane (MOM). As a consequence, the mitochondrial matrix displays an increased pH and the MIM has a highly negative-inside membrane potential (Dw). (C)
Together, the pH (DpH) and potential difference (Dw) across the MIM determine the magnitude of the proton-motive force (PMF), which is used by the FoF1-ATPase
(complex V) to drive mitochondrial ATP production from inorganic phosphate (Pi) and ADP. In addition to ATP generation, virtually all other mitochondrial processes
including ion exchange and pre-protein import require a proper DpH and/or Dw. The magnitude of the PMF not only depends on the combined action of the ETC and
complex V (i.e., the oxidative phosphorylation system; OXPHOS) but also is affected by other electrogenic systems. These include uncoupling proteins (UCPs), the Pi
transporter (PiT), and the adenine nucleotide translocator (ANT). This figure was compiled based on (Koopman et al, 2010; Valsecchi et al, 2010; Liemburg-Apers et al,
2011; Koopman et al, 2012, 2013 and Liemburg-Apers et al, 2015).
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the excretion of TCA cycle intermediates in urine, and (iii) detailed
investigations of affected organs and tissues by medical specialists
like neurologists, ophthalmologists, cardiologists, and/or by imag-
ing techniques such as echocardiography or magnetic resonance
imaging (MRI) of brain, heart, and skeletal muscle, and by neuro-
physiological studies (such as obtaining an electroencephalogram;
EEG). The decision to perform a skeletal muscle biopsy for
histopathological, immunohistochemical, and/or enzymological
analysis is taken based on the “Bernier” or “Wolf/Smeitink” mito-
chondrial disease criteria (MDC; Bernier et al, 2002; Wolf &
Smeitink, 2002), which might include biochemical (e.g., ATP
production rate) and general criteria (e.g., clinical presentation) to
establish the probability of a mitochondrial disease. Biochemical
analysis usually includes spectrophotometric activity analysis of
individual OXPHOS complexes. Blue Native-PAGE, which can be
used to assess the relative amount of fully assembled OXPHOS
complexes, can also be a useful tool (e.g., van Rahden et al, 2015).
In addition to muscle tissue, enzymes are often examined in
cultured skin fibroblasts. In combination with a muscle biopsy, both
positive and negative fibroblast results are informative with respect
to predicting the underlying genetic defect. Genetic analysis can be
carried out either by traditional candidate gene sequencing, or by
more comprehensive approaches including direct (whole) exome
sequencing (in which all coding regions in the genome are
sequenced) or whole-genome sequencing, often followed by func-
tional complementation analysis in patient-derived cells.
The impact of whole-exome sequencing
The implementation of whole-exome sequencing as a routine molec-
ular diagnostic test for mitochondrial disorders has resulted in the
identification of numerous variants in many different genes (DaRe
et al, 2013; Lieber et al, 2013; Ohtake et al, 2014; Taylor et al, 2014;
Wortmann et al, 2015). Genetic variants include known pathogenic
mutations, the clinical/biochemical phenotype of which matches
those described in the literature and public databases. In this case,
the diagnosis is clear and no further functional tests are necessary.
When an unknown gene variant is encountered, there are several
possibilities: (i) the variant occurs in a gene that is associated with a
known disease and interferes with the function of the gene product;
again, this means that no additional functional tests are necessary,
(ii) the variant results in an amino acid change at the protein level or
possibly interferes with the expression of a disease-associated gene
and/or the splicing of its mRNA; this means that the consequences
of the variant are not unambiguously predictable and a functional
test can help to establish the diagnosis, (iii) the variant occurs in a
gene of unknown function or a gene not previously associated with
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Figure 2. Currently identified mutations in nDNA-encoded OXPHOS subunits and assembly factors causing mitochondrial disease in children.
OXPHOS structural subunits in which a pathological mutation was reported are depicted in red for each complex. Assembly factors are indicated (in blue). The data in this
figure were compiled from (Koopman et al, 2012, 2013; Mayr et al, 2015; Ostergaard et al, 2015; van Rahden et al, 2015).
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disease; this means that the diagnosis requires a functional confir-
mation of the defect. In general, mitochondrial disorders display a
poor correlation between genotype and phenotype. This further
emphasizes the importance of functional validation of genetic
variants (Daud et al, 2015). For genes known to be mutated in
OXPHOS disease, the possibility to perform relatively low-cost diag-
nostic exome sequencing using DNA extracted from blood samples
has certainly sped up and facilitated the diagnostic process
(Wortmann et al, 2015). However, it is important to realize that
when a negative result is obtained, this does not conclusively rule
out the presence of a mitochondrial disease. This is caused by the
fact that: (i) the exome sequencing technique displays non-optimal
coverage meaning that mutations in non-covered parts of the
exome cannot be excluded, (ii) even a whole exome covers only
approximately 1% of the whole genome, (iii) the pathophysiologi-
cal effects of many polymorphisms are unknown, and (iv) the
number of mutated genes demonstrated to be involved in mito-
chondrial disease is continuously increasing. As an example of the
latter, we demonstrated that a patient with intellectual disability
and multisystemic problems displayed an isolated enzymatic
complex IV deficiency caused by a pathological mutation in the
centrosomal protein of 89 kDa (CEP89), previously not associated
with mitochondrial dysfunction (van Bon et al, 2013). As a conse-
quence, it becomes increasingly difficult to classify mitochondrial
diseases in children based upon their phenotypic presentation.
Therefore, the number of patients that will be correctly diagnosed
with a mitochondrial (OXPHOS) disease will be underestimated. A
possible solution to this problem could be that patients for whom
an obvious explanation for their symptomatology cannot be estab-
lished are referred to specialized (inter)national centers of excel-
lence (e.g., the Radboud Center for Mitochondrial Medicine in the
Netherlands), which can decide on an appropriate cost- and time-
effective diagnostic strategy.
The relevance of complementation studies
Genetic complementation studies are carried out by introducing
the wild-type DNA of the mutated gene into patient-derived cells
(usually skin fibroblasts). DNA transduction by lentiviral trans-
mission is an efficient way to achieve genetic complementation
(e.g., Jonckheere et al, 2011). Although it is relatively time-
consuming, this procedure yields a population of stably comple-
mented cells. Transient transfections can also be used, for
instance, using an insect virus (baculovirus) system (e.g., Kirby
et al, 2004; Hoefs et al, 2008). In this approach, the protein
to-be-overexpressed can be tagged with a fluorescent protein
(e.g., Hoefs et al, 2008), or be part of an IRES (internal ribosome
entry site)-containing construct (e.g., Bouabe et al, 2008). Using
the IRES strategy allows simultaneous expression of the protein
and a fluorescent marker protein without them being physically
attached to each other. Although with a transient transfection
protocol, not all cells are necessarily transfected, it can be advan-
tageous when a microscopic readout is used since it allows side-
by-side comparison of transfected (complemented) and non-trans-
fected (non-complemented) patient cells. Depending on the nature
of the mutation, functional confirmation of pathogenicity can
obtained using a relatively simple readout like enzymatic activity
(Haack et al, 2012; Ngu et al, 2012; Jonckheere et al, 2013;
Szklarczyk et al, 2013) or protein expression levels (assessed by
Western blotting; Hoefs et al, 2008). More advanced strategies
include comparative analysis of control, patient, and comple-
mented patient primary fibroblasts with respect to mitochondrial
morphology (Koopman et al, 2005; Jonckheere et al, 2011) and
Dw (Hoefs et al, 2008). Unfortunately, functional studies of the
genetic defect are often lacking in published studies, especially
when a large number of patients have been analyzed. Although
large-scale complementation and other functional studies may be
practically challenging, they should be carried out to prevent
detected variants prematurely or erroneously ending up in patho-
genic mutation databases. For example, a recent study described
two novel mutations in SCO2 (a complex IV assembly gene) in
patients with early-onset myopia (Jiang et al, 2014). Although the
authors did state that additional studies are needed to prove the
pathogenicity of these (and other) mutations, the latter are never-
theless listed in the Human Gene Mutation Database (HGMD) as
“disease-causing” (www.hgmd.cf.ac.uk). This is not to criticize
mutation databases as these are extremely valuable to clinical
practice, but to illustrate that clinicians and laboratory specialists
should remain critical about the information provided by these
databases. Similarly, in publications dealing with genetic variants,
incorrect or incomplete information can have important clinical
implications for individual patients.
Cellular pathophysiology of OXPHOS dysfunction
During the last 15 years, we have strongly advocated the use of
living cells (in addition to cell homogenates, isolated mitochondria,
and fixed tissue samples), to study the pathophysiology of mito-
chondrial dysfunction in general and OXPHOS mutations in particu-
lar (e.g., Smeitink et al, 2004; Koopman et al, 2010, 2012, 2013;
Willems et al, 2015). Live-cell analysis is crucial since mitochon-
drial and cellular functions are tightly interconnected. This is illus-
trated by the following observations: (i) mitochondrial morphology
and function are altered by isolation procedures, (ii) the cellular
environment is required to provide substrates to mitochondria and
the OXPHOS system, (iii) mitochondria exchange ions and metabo-
lites (e.g., ADP, Pi and ATP) with the cytosol, and (iv) mitochon-
drial and cellular functioning are linked and controlled by
(retrograde) signaling pathways (e.g., Palmieri, 2008; Koopman
et al, 2010; Picard et al, 2011; Szabo & Zoratti, 2014). In principle, a
mutation in an OXPHOS protein-encoding gene can reduce the cata-
lytic activity of the OXPHOS complex, its protein levels, or both. In
case of isolated complex I deficiency, the reduction in the levels of
fully assembled complex I in primary patient fibroblasts was linked
to a proportional decrease in complex I residual activity (e.g.,
Valsecchi et al, 2010). This suggests that mutations in nDNA-
encoded complex I subunits reduce the biosynthesis of fully active
complex I and/or induce complex I destabilization (i.e., an “expres-
sion defect”). Only in a single case (i.e., a patient carrying an
Asp446Asn mutation in the NDUFS2 gene of complex I), a reduced
complex I activity was not paralleled by a lower level of fully assem-
bled complex I (i.e., a “catalytic defect”; Ngu et al, 2012). Quantita-
tive live-cell microscopy of primary fibroblasts from 14 control
subjects and 24 children with isolated complex I deficiency revealed
that patient cells displayed a less negative Dw (i.e., “depolarization”),
increased mitochondrial NADH levels, elevated reactive oxygen
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(ROS) levels, aberrations in mitochondrial morphology, and
disturbed cytosolic and mitochondrial Ca2+ and ATP handling
(Koopman et al, 2005, 2007, 2008; Verkaart et al, 2007a; Golubitzky
et al, 2011; Valsecchi et al, 2010; Roestenberg et al, 2012; Leman
et al, 2015). Interestingly, several of the above aberrations were also
observed in fibroblasts carrying mutations in other OXPHOS
complexes and assembly factors (e.g., Szklarczyk et al, 2013), in
mouse cells with genetic complex I deficiency (e.g., Kruse et al,
2008; Valsecchi et al, 2012, 2013), in cells treated with OXPHOS
inhibitors (e.g., Forkink et al, 2014, 2015; Distelmaier et al, 2015;
Scho¨ckel et al, 2015), and in cells with mutations in non-OXPHOS
mitochondrial proteins (e.g., Mortiboys et al, 2008; Heeman et al,
2011; Hoffmann et al, 2012). This suggests that, depending on the
cellular context and experimental conditions, the observed aberra-
tions in primary skin fibroblasts of patients with inherited complex I
deficiency reflect the “general” consequences typical of mitochon-
drial dysfunction. Correlation analysis suggested that NADH and
ROS levels increased as a direct consequence of the reduced expres-
sion of fully active complex I (Verkaart et al, 2007a,b). Moreover,
patient fibroblasts with a moderate reduction in complex I activity
displayed a much smaller increase in ROS levels than fibroblasts
with a large reduction in complex I activity (Koopman et al, 2007).
In addition, mitochondrial morphology was not affected and
appeared fragmented when complex I activity was moderately and
greatly reduced, respectively (Koopman et al, 2007). Integrated
analysis of cellular and clinical data revealed that fibroblasts
from patients with a relatively early age of disease onset/death
displayed a large reduction in complex I activity. Similarly,
patients with a later age of disease onset/death displayed a
much smaller reduction in complex I activity (Blanchet et al,
2011). The same study revealed that the extent of complex I
deficiency was proportional to the cellular level of OXPHOS
proteins and inversely related to cellular NADH/ROS levels and
degree of mitochondrial fragmentation.
Taken together, the above results suggest that complex I activ-
ity in patient fibroblasts might be improved by reducing the
increased ROS levels and normalizing mitochondrial morphology.
Indeed, treating patient fibroblasts with the water-soluble vitamin
E-derived antioxidant Trolox (6-hydroxy-2,5,7,8-tetramethyl-
chroman-2-carboxylic acid) reduced ROS levels and increased the
expression of fully assembled complex I and thereby complex I
activity (Koopman et al, 2008). A follow-up study demonstrated
that Trolox treatment reversed Dw depolarization and normalized
Ca2+-stimulated ATP production in patient fibroblasts (Distelmaier
et al, 2009). Further mechanistic analysis revealed that ROS and
thiol redox state co-control mitochondrial morphology and func-
tion in human skin fibroblasts (Distelmaier et al, 2012; Willems
et al, 2013), compatible with the apparent link between ROS levels
and regulation of mitochondrial morphology and function
(Willems et al, 2015). This suggests that the reduced complex I
activity, increased ROS level, and altered mitochondrial morphol-
ogy, and possibly also other aberrations, might constitute linked
therapeutic targets (Koopman et al, 2007; Blanchet et al, 2011,
2015). We thus pursued antioxidant treatment as a potential
strategy to mitigate the cellular aberrations in fibroblasts from
patients with isolated complex I deficiency. This is discussed
further in the section on the development of the novel antioxidant
KH176 (see below).
Development of treatments
Overall strategy
A “lead compound” is a chemical molecule displaying pharmacolog-
ical or biological activity likely to be therapeutically useful, but with
a suboptimal chemical structure that requires modification to
acquire better drug-like properties. Such properties would include
efficacy, potency, safety, synthesis route, cost, chemical stability,
metabolic stability, and, last but not least, patentability (Pritchard
et al, 2003). During optimization, the primary selection criterion is
usually based on compound efficacy and potency. However,
compounds active in one assay may perform poorly in others, indi-
cating that their selection needs to be based on multiple properties.
Lead optimization and selection mainly depend on the properties of
the molecule in studies involving its absorption, distribution, meta-
bolism, and excretion (ADME properties), its pharmacokinetics (PK)
profile, and in vitro safety. Unfortunately, there are no predictive
rules for identifying a potentially successful compound. During the
selection process, certain additional constraints can be applied
depending on the desired in vivo properties of the small molecule.
These include the preferred route of administration (e.g., oral
bioavailability), the targeted organs (e.g., blood–brain permeabil-
ity), or potential drug–drug interactions in the studied disease
group. Importantly, a certain amount of specific preclinical informa-
tion is necessary to fulfill the requirements of the ethical/regulatory
authorities involved and allow proceeding to the next development
phase. To illustrate this process, we here present some of our own
experiences in further developing an active pharmaceutical ingredi-
ent (API) following lead optimization. This consists of the following
steps (Table 1):
• Metabolic profiling in hepatocytes of humans and various animal
species will assist in deciding which animal species to use during
the regulatory toxicology phase, in which the API’s toxic potential
is assessed. As any metabolite can cause toxicity, the combined
metabolites detected in two selected animal species should cover
all potential metabolites in humans.
• Scaling up of API synthesis according to GMP (good manufactur-
ing practice) standards, acquiring CMC (chemistry and manufac-
turing controls) information of the API, and determining API
stability. Information obtained during these three steps is crucial
for defining the formulation of the API and obtain authorization
to enter the clinical trial phase. Producing a GMP batch of the API
is not mandatory for the non-clinical toxicology phase but it is
strongly advised to use the same GMP batch for both regulatory
toxicology studies and the early trial clinical phases. This relates
to the fact that it needs to be demonstrated that various GMP
batches display an identical (im)purity profile.
• Optimization of a good laboratory practice (GLP)-compliant
method of detection of the API in blood or plasma in order to
study its pharmaco- and toxicokinetic profile during non-clinical
toxicology and clinical trials.
• Performing a non-clinical regulatory toxicology study. This study
will be designed based on specific toxicity information obtained
during in vitro or in vivo screening and the intended patient
populations (e.g., reproductive toxicology or juvenile toxicol-
ogy). The duration of this study will depend on the expected
duration of the treatment in patients during clinical trials and
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Table 1. Steps in the development of active pharmaceutical ingredients (APIs) toward clinical use.
Phase Subphase Activities Outcomes
Lead optimization (non-GLP) In vitro ADME Chemical stability, solubility, metabolic
stability, stability in gastric environment,
CYPs interaction, PPB, BBB permeability
Information required for the final
selection of the lead compound; it is
usually performed on a group of the most
potent hit analogs developed during the
hit-to-lead screen
In vitro toxicology Cytotoxicity, hepatotoxicity, cardiotoxicity,
mutagenicity
In vivo ADME Pharmacokinetics: (oral) bioavailability,
plasma exposure, tissue distribution,
metabolism, excretion
Metabolite profiling N.a. Profiling and identification of metabolites
formed in hepatocytes of humans and
animal species used for non-clinical safety
Allows the selection of animal species for
further in vivo toxicology studies
Synthesis scale-up (GMP) N.a. Synthesis of a large batch of API in a GMP
fashion
A GMP batch of API produced in quantity
sufficient to cover the toxicology and
First-in-Human studies
CMC of the API N.a. Validation of API chemical structure;
determination of physicochemical
parameters
Mandatory information for IB/IMPD or
IND filling and for formulation
development
API stability N.a. Stability study of the API under ICH
conditions
Expiry date of the API in different storage
conditions
Pre-formulation and
stability of drug product
N.a. Selection of the formulation based on
physicochemical properties of the API and
desired route of administration;
determining API stability in the formulation
Optimal formulation and stability data to
support GLP toxicology and First-in-
Human studies
GLP-compliant API
detection methods
N.a. Validation of a GLP-compliant method to
quantify the API in dose formulation studies
and biological fluids
GLP-compliant and validated method to
detect and quantify API during toxicology
and First-in-Human trials
Non-clinical safety Pilot toxicology study Dose range finding and 14-day toxicology
study in a single animal species
First information on the dose range and
specific toxicity to be monitored during
the next phases
GLP-compliant regulatory
toxicology study
In vitro: GLP-compliant in vitro toxicology
study
Genetic toxicology, safety pharmacology
In vivo: GLP-compliant in vivo toxicology General toxicology
In vivo: reproductive toxicology study Adverse effects on embryonic
development
In vivo: juvenile toxicology study Specific adverse effect on juvenile
population
Drug–drug interaction study N.a. Inhibition and substrate potential of API
toward CYPs, drug transporters, and UGTs
Prediction of potential adverse effect
arising from polypharmacology (i.e., how
others drugs and API will impact on each
other’s ADME properties leading to
modified PK/PD profile)
Investigational brochure (IB) N.a. Compile all preclinical data relevant to
study the API in humans under ICH
conditions
The IB is required for the clinical
investigator to design the clinical trial
protocol
Investigational medical
product dossier (IMPD)
N.a. Complete the IMPD form with CMC
information about drug substance and drug
product
The IMPD is required for authorization to
enter First-in-Human trials
Clinical trial application (CTA) form N.a. Complete CTA with information about drug
product and trial design, site and
investigator
The CTA is required to obtain
authorization to enter First-in-Human
trials
This table summarizes the overall preclinical experimental and administrative steps required for a novel API to entering First-in-Human trials. It is based upon
experiences within our SME Khondrion and is not intended to be exhaustive. Each API will have a specific development path, and API developers should strictly
follow the guidance and requirements from the official agencies involved.
ADME, absorption, distribution, metabolism, and excretion; API, active pharmacological ingredient; BBB, blood–brain barrier; CMC, chemistry and manufacturing
controls; CTA, clinical trial application; GLP, good laboratory practices; GMP, good manufacturing practices; CYP, cytochrome P450; IB, investigational brochure;
ICH, The International Conference on Harmonisation (of Technical Requirements for Registration of Pharmaceuticals for Human Use); IMPD, investigational
medical product dossier; IND, investigational new drug; N.a., not appropriate; PD, pharmacodynamics; PK, pharmacokinetics; PPB, plasma protein binding; UGT,
UDP glucuronosyltransferase.
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will help to determine the safe starting dose for administration
to humans.
• Investigating drug–drug interactions (DDI). The different medicine
authorities have issued strict guidelines regarding these studies.
Although not mandatory for clinical phase 1 studies (healthy
volunteers), DDI studies are of crucial importance prior to execut-
ing patient trials (phase 2 clinical trials and beyond). This is to
avoid potential API toxicity due to interaction with medications or
deficiencies in liver or kidney metabolism.
• Compiling the investigational brochure (IB). This contains all
preclinical (pharmacology and toxicology) data relevant for use of
the API in the clinic. The IB will be continuously updated during
clinical development.
• Compiling the investigational medical product dossier (IMPD).
This dossier contains all physicochemical and drug formulation
information of the API.
• Completing the clinical trial application (CTA) form. The CTA
contains information about the drug product, trial design, and
investigator details. Together with the IMPD, the CTA is required
for approval of the clinical trials.
Designing clinical trials
Before an API obtains market approval and can therefore be
prescribed by clinicians, in-human studies have to be performed.
Classically, these studies consist of four phases. In phase 1, API
pharmacokinetics and dynamics (including toxicity) are determined
in healthy volunteers. During phase 2, the intention is to determine
the efficacy of the API in a small and homogeneous patient group.
Phase 3 seeks to confirm the effectiveness and safety of the API on
clinically relevant outcome measures in a large and more heteroge-
neous group of patients. The results of phase 3 are mostly used to
apply for market authorization. Following market authorization, the
(long-term) safety and efficacy of the drug remain to be monitored
(phase 4). One of the most challenging aspects of clinical trials
involves the selection, validation, and application of clinically rele-
vant outcome measures.
Outcome measures
Outcome measures provide information about certain disease
aspects, such as severity, response to therapy or remission (Brunner
& Ravelli, 2009). In case of frequently occurring disease (e.g.,
cardiovascular disease, cancer), the time-to-event (relapse, stroke,
myocardial infarction, death), histology, or radiological results are
often used as outcome measures (Preiss et al, 2011; Fernandez-
Martos et al, 2012; Etzioni et al, 2015). Obviously, the credibility of
a clinical trial greatly depends on the chosen outcome measures and
the strategy that is used to quantify them (Tugwell & Boers, 1993).
In general, the number of patients required for a clinical trial (sam-
ple size) depends on the magnitude of the expected effect relative to
the precision of the used measurement. This means that either the
treatment should produce a large effect or the used outcome
measures should be very precise when only a small patient cohort is
available, as is the case for children with OXPHOS disease. More-
over, if the therapy under development slows down disease progres-
sion rather than reducing morbidity (Friedman et al, 2010; Kang,
2013), it becomes challenging to identify outcome measures suited
for quantitative analysis. In addition, children are continuously
growing and developing (meaning that age-specific tests and age-
and size-matched reference values are required) and their under-
standing and enthusiasm, as well as their cooperation, can affect the
test results. Since virtually all the functional tests require the child
to perform at his/her maximal level, children with mild mental
disability might not give consistent results because of attention defi-
cits and a lack of understanding the importance of the tests. Measur-
ing disease progression in children that are severely mentally
disabled and sometimes not able to communicate is virtually impos-
sible. In general, the outcome measures not only depend on the
disease stage or disability grade but also on age, gender, intellectual
abilities, environment, and personal factors. To the best of our
knowledge, there are no established outcome measures that corre-
late with disease progression in mitochondrial dysfunction (Lee
et al, 2010; Augustine et al, 2013; Koene et al, 2014, 2015). In case
of mitochondrial OXPHOS disorders with neuromuscular dysfunc-
tion, the regulatory authorities [i.e., the European Medicines Agency
(EMA) and the American Food and Drug Adminstration (FDA)]
advise using the 6-min walking test (6MWT) as a primary outcome
measure. This test measures the total distance an individual is able
to walk during 6 min on a hard and flat surface (Balke, 1963). In
other disease fields (e.g., Dubrovsky et al, 2013; Alfano et al, 2014),
as well as in our own experience with OXPHOS disease patients
(Dirks et al, 2015), the 6MWT showed a considerable test–retest
variability and lack of sensitivity. Therefore, we expect that other
approaches like accelerometry, continuously measuring the physical
activity of the child in their home environment, or measuring
detailed gait characteristics are more appropriate to detect
subtle but clinically relevant changes in disease severity (S. Koene
et al, unpublished findings). In addition we have selected several
clinically relevant and robust outcome measures to be used in clini-
cal trials with children suffering from mitochondrial disease. These
outcome measures were chosen based upon the most burdensome
complaints/symptoms according to the patients and their parents
(Koene et al, 2013a), and on the results of validation studies in
Duchenne muscular dystrophy and cerebral palsy, which were used
as a model for mitochondrial myopathy and mitochondrial
encephalopathy, respectively. The total set of outcome measures
can be divided into a “common core set” including the following:
accelerometer test, 6MWT test, Gross Motor Function Measure
(GMFM) and Medical Research Council (MRC) scale; and a number
of “optional tests” including: forced vital capacity, Child Health
Questionnaire, and growth charts (Koene et al, 2013b). The validity
of these outcome measures was assessed in several studies (Dirks
et al, 2015; S. Koene et al, unpublished findings), which suggested
that accelerometry and 2-dimensional (2D) speckle tracking
echocardiography (Blessberger & Binder, 2010) are feasible instru-
ments to monitor disease progression, but the assisted 6-minute
cycling test is not. The currently available diagnostic biomarkers for
mitochondrial disease (i.e., GDF15, FGF21) do correlate with
disease severity. However, these biomarkers appear not to be suited
for monitoring disease progression since the change in the concen-
tration of neither biomarker correlated to the change in disease
severity (Koene et al, 2014, 2015). Additional validation studies are
required to guide the further selection of outcome measure(s) for
use in clinical trials involving children. Obviously, this selection is
highly dependent on the mode of action of the API being tested and
is preferably made by integrating the expertise of pediatricians and
EMBO Molecular Medicine Vol 8 | No 4 | 2016 ª 2016 The Authors
EMBO Molecular Medicine Treatment of pediatric OXPHOS disorders Werner JH Koopman et al
318
Published online: March 7, 2016 
other medical specialists, statisticians, regulatory experts, industry
partners, and patient/parent representatives.
Study population
In case of mitochondrial OXPHOS diseases, only a low number of
patients are available for phase 2 clinical trials. This means that low
patient-to-patient variation is required to demonstrate the potential
efficacy of a small molecule. In the ideal case, the used patient
cohort should display a homogeneous genotype, phenotype, disease
stage, and organ specificity. Preferentially, the patients should
neither be on medication nor display liver or kidney failure (Pfeffer
et al, 2013). However, mitochondrial OXPHOS syndromes with a
relatively high level of homogeneity for which a reasonable number
of patients are available (e.g., Leber’s hereditary optic neuropathy;
LHON) are uncommon and hardly any of them is pediatric. Given
this fact, the difficulty of assessing outcome measurements in chil-
dren (see above), and ethical and regulatory considerations, phase 2
clinical trials should preferentially be carried out first in adult mito-
chondrial disease patients. In addition to mitochondrial syndromes
caused by OXPHOS mutations, also other rare pediatric syndromes
exist. An example of such a disease is Barth syndrome, caused by a
mutation in the TAZ gene. The latter encodes the tafazzin protein,
which is involved in the synthesis of the mitochondrial lipid cardio-
lipin. Clinically, Barth syndrome appears to display a reasonably
homogeneous phenotype characterized by skeletal muscle weak-
ness, cardiomyopathy, neutropenia, and growth delay (Barth et al,
1983; Spencer et al, 2006; Roberts et al, 2012; Jefferies, 2013;
Rigaud et al, 2013). This suggests that a Barth syndrome patient
cohort might be suited for phase 2 clinical trials. On the other hand,
because OXPHOS dysfunction in Barth syndrome is a consequence
of mitochondrial membrane alterations, such a cohort might not be
the best choice for drug efficacy analysis since the obtained results
might not be generalizable to primary OXPHOS disorders. Alterna-
tively, Kearns Sayre syndrome is another more or less homogeneous
mitochondrial disease that is characterized by ophthalmoparesis,
pigmentary retinopathy, deafness, muscle weakness, ataxia, and
cardiac conduction block (Yamashita et al, 2008). Although not
strictly pediatric (i.e., it can manifest itself in children and adoles-
cents), the progression of Kearns Sayre syndrome appears to be
reasonably stable (Grady et al, 2014). Since most Kearns Sayre
syndrome patients are mentally competent, the feasibility and ethi-
cal acceptability of clinical trial is increased. However, separate
studies will have to be performed in neonates, infants, and young
children. Another strategy is to include all children diagnosed with
a mitochondrial disorder, regardless of their genetic or biochemical
diagnosis, using very strict clinical inclusion criteria. The latter can
include that the child: (i) has a stable disease course in the past
year, (ii) can follow instructions such as hopping on one leg or
rotating a pen in the hand, (iii) scores a 6MWT value between the
age- and height-matched 5th and 10th percentile, and/or (iv) a
GMFM score between 15 and 25%. Such an approach requires a
separate neonatal study, including for example neonates with infan-
tile mitochondrial lactic acidosis, since the pharmacokinetics, safety,
and efficacy in neonates might differ from the other (pediatric)
groups. For all phase 2 trials, it is crucial to realize that children are
clinically and physiologically not equivalent to “small adults”. This
means that designing a proper drug administration regime requires
separate studies on drug formulation, safety, and pharmacokinetics.
Study design
In case of pediatric OXPHOS disease, it is difficult, if not impossible,
to carry out classical randomized control clinical trials since these
require relatively large homogeneous patient cohorts. However, alter-
native trial designs are applicable (Chow & Chang, 2008; Gupta et al,
2009; Cornu et al, 2013). In the “crossover” and “n-of-1” designs,
each patient serves as its own control and receives both placebo and
active drug treatment, which facilitates recruitment. Whereas a cross-
over study aims to determine the efficacy of a drug in a group of
patients, an n-of-1 study aims to determine drug effects within a
single subject, although the results of multiple n-of-1 studies can be
used for meta-analysis (Gupta et al, 2009). Formally, crossover and
n-of-1 designs can only be applied if the disease status is similar
between the start of the first and the second treatment phase (i.e.,
similar baseline measurements before the placebo or active drug
phase). In this sense, they are less compatible with pediatric mito-
chondrial OXPHOS disorders. However, if the duration of the drug
treatment and the washout period (being the time between the treat-
ment phases in which the drug and the long-term drug effects are
eliminated from the body before the start of the second phase) is
short, and no long-term effects of treatment are expected (i.e., mini-
mal carryover effect), these designs may be of great value when eval-
uating drug efficacy in mitochondrial disease. If feasible, larger and
phenotypically homogeneous cohorts can be analyzed in crossover
studies. In ultra-rare mitochondrial syndromes or those with a hetero-
geneous phenotype, n-of-1 trials are most suitable. In both cases,
patients with an obviously oscillating disease course should be
excluded. When choosing a crossover or n-of-1 design, several other
methodological issues should be covered. First of all, the sequence of
the placebo and the active treatment phases should be randomized to
correct for confounders such as seasonal influences and (unexpected)
learning effects. In case of group comparisons, such as in a crossover
study, randomization should be stratified based on predefined crite-
ria, in order to create comparable groups. Secondly, since all of the
above-mentioned study designs are subject to report bias, blinding of
both investigators and patients is of great importance, especially in
case of subjective end points. Finally, since the outcome measure is
applied multiple times within the same subject, the outcome
measures should be tested for learning processes, which is expected
to be the case for, for example, the 6-min walking test (Casey et al,
2012). Another design is the “Bayesian trial design” (Berry, 2006),
which gives information about the probability that a predefined
change occurs (e.g., the chance that the GMFM score is 10% higher
after 4 weeks of active treatment compared to the placebo condition).
Although the Bayesian design might still be unfamiliar to regulatory
authorities and clinical investigators, its flexible design and smaller
sample sizes make it a promising design for phase 3 trials.
A case study: the development of KH176
Obviously, results obtained with (patient-derived) cell lines (as any
other model system including mice) should be treated with caution
when translating to human pathology. As mentioned above, we
hypothesized that treatment with the vitamin E-derived antioxidant
Trolox might be a viable starting point for the rational development
of small molecules that correct or mitigate the cellular consequences
of nDNA-encoded complex I mutations. To allow its effective use in
animal models and human subjects, we developed a first library of 20
novel Trolox variants, several of which displayed increased potency
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and efficacy in scavenging cellular ROS. However, small chemical
molecules generally induce multiple subtle effects. This means that
techniques like single-parameter high-throughput cell screening and
in vitro potency analysis are not generally predictive to identify the
most optimal molecules. By combining automated image quan-
tification and machine learning techniques, we were able to discrimi-
nate between the mitochondrial morpho-functional phenotype of
fibroblasts of a healthy individual and a Leigh syndrome patient
(Blanchet et al, 2015). Application of this strategy highlighted Trolox
ornithylamide hydrochloride (KH003) as a hit compound that effec-
tively scavenged ROS and increased the maximal activity of mito-
chondrial complex I, complex IV, and citrate synthase. Next, a
second generation of compounds was developed to further improve
the drug-like properties and potency of KH003 by modifying its chem-
ical structure through classical medicinal chemistry. The lead opti-
mization was targeted and prioritized toward the improvement of
solubility, cell permeability, oral bioavailability, blood–brain barrier
permeability, and chemical stability. The potency and efficacy of this
2nd-generation library in scavenging cellular ROS and protecting cells
against oxidative stress was again analyzed in Leigh syndrome
patient fibroblasts. This strategy finally yielded KH176 as a lead
compound since it displayed the best compromise between potency,
drug-like properties and the in vitro therapeutic window (i.e., the
space between potency and toxicity). Following successful regulatory
toxicology analysis, KH176 has entered the clinical trial phase
(www.clinicaltrials.gov; NCT02544217) and recently successfully
completed the clinical trial phase 1.
Small molecules for treatment of mitochondrial disease
In addition to KH176, various small molecules for treatment of
mitochondrial diseases are currently being evaluated in clinical
studies (Kerr, 2013; Rai et al, 2015). These include idebenone, EPI-
743, MTP-131, RP103, coenzyme Q10, bezafibrate, RG2133, DCA,
ARG/CIT, lipoic acid, RTA408, and curcumin (Table 2).
• Idebenone can act as an antioxidant and delivers electrons directly
to complex III, thereby bypassing a deficient complex I (Giorgio
et al, 2011; Haefeli et al, 2011; Jaber & Polster, 2015). This
compound has recently received market approval in Europe for
the treatment of LHON. It is also under clinical investigation for
the treatment of MELAS (phase 2a studies) and Friedreich ataxia
(phase 3 studies).
• EPI-743 functions as a cofactor of the enzyme NAD(P)H dehydro-
genase Quinone 1 (NQO1) and enhances the biosynthesis of
glutathione (GSH), which is an important cellular antioxidant
(Pastore et al, 2013). EPI-743 is currently evaluated in clinical
phase 2 studies in various indications such as Leigh, LHON, and
Pearson syndrome. Promising results though from initial single
open-label trials in patients suffering from Leigh syndrome (Enns
et al, 2012; Martinelli et al, 2012) or LHON syndrome (Sadun
et al, 2012) have been reported.
• MTP-131 is a member of the Szeto-Schiller (SS) peptide family
and binds to the mitochondria-specific MIM lipid cardiolipin
(Alam et al, 2015). It increases OXPHOS efficiency and potentially
improves the ability of mitochondria to properly respond to meta-
bolic changes. Using different formulations, MTP-131 has entered
clinical trials for the treatment of mitochondrial myopathies
(phase 1/2) and LHON (phase 1/2). In pre-clinical studies,
MTP-131 corrected excessive ROS generation and increased ATP
production in mitochondrial dysfunction (Szeto, 2014).
• RP103 is intended to supply the cell with additional cysteine, an
important amino acid for GSH neosynthesis (Besouw et al, 2012).
RP103 is currently being evaluated in the form of delayed-release
capsules in the treatment of children with inherited mitochondrial
disease, including Leigh syndrome (phase 2/3).
• Coenzyme Q10 is an ETC component involved in electron trans-
port (Fig 1B), which also displays antioxidant capacity. It is avail-
able without prescription and has been evaluated in a phase 2
study on adult patients with mitochondrial cytopathies (MELAS,
LHON, and chronic progressive external ophthalmoplegia; CPEO),
showing minor improvement (Glover et al, 2010). A phase 3
study (Stacpoole et al, 2012) has been completed in children with
primary mitochondrial diseases but, as far as we know, no results
have been reported yet.
• Bezafibrate is a known activator of the transcription factor peroxi-
somal proliferator-activated receptors (PPARs; Wenz et al, 2008).
When activated, PPARs induce transcription of genes involved in
mitochondrial function including fatty acid metabolism. Effects of
bezafibrate are conflicting, since it both displayed adverse effects
and positive effects in various studies (Wenz et al, 2008; Viscomi
et al, 2011; Yatsuga & Suomalainen, 2012). The therapeutic poten-
tial of bezafibrate is currently evaluated in an open-labeled phase
2 study on patients carrying the mtDNA 3243A>G mutation. The
latter mutation is one of the most common mtDNA mutations in
mitochondrial disease and is causatively linked to MELAS, CPEO,
and maternally inherited deafness and diabetes (MIDD; Nesbitt &
McFarland, 2011).
• RG2133 or 20,30,50-tri-O-acetyluridine is a precursor of uridine, a
pyrimidine nucleotide involved in RNA and DNA synthesis.
Endogenous uridine synthesis depends on coenzyme Q10 recycling
and normal OXPHOS function. This means that OXPHOS dysfunc-
tion can impair uridine synthesis leading to cellular dysfunction.
The assessment of RG2133 safety and efficacy in a phase 1 study
on patients with mitochondrial disease was terminated. As far as
we know, no results have been reported.
• DCA (dichloroacetate) is a structural analog of pyruvate. This
molecule locks PDHC (which converts pyruvate into acetyl-coA),
in an active state by inhibiting pyruvate dehydrogenase kinase.
This might improve OXPHOS function despite the presence of
PDHC or OXPHOS defects. A randomized controlled phase 2 trial
in patient suffering from MELAS was terminated prematurely
because of peripheral nerve toxicity (Kaufmann et al, 2006).
• ARG/CIT (L-arginine/L-citrulline) are precursors of nitric oxide
(NO), an important cellular-signaling molecule involved in vasodi-
lation. Therefore, increased NO production following supplemen-
tation with ARG/CIT is hypothesized to protect MELAS patients
against recurrent strokes possibly due to vasoconstriction. Open-
label studies in MELAS patients have shown promising results
(Rodan et al, 2015), but still need be performed under well-
controlled conditions to draw final conclusions.
• Lipoic acid displays antioxidant activity in vivo (Koufaki, 2014).
This compound was evaluated in a combination treatment with
creatine and coenzyme Q10 during a phase 2 randomized and
controlled trial on patients with mitochondrial cytopathies
(Rodriguez et al, 2007). During this trial, positive effects on
surrogate markers of oxidative stress were observed. It was also
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Table 2. Small molecules used in clinical studies for treatment of mitochondrial diseases.
Molecule name
Targeted
disease Clinical phase
Clinical trial
identifiera Primary results Sponsor
KH176 MELAS Phase 1 double-blind,
randomized, placebo-
controlled study of the
safety, tolerability,
pharmacokinetics, and
pharmacodynamics in
healthy volunteers
NCT02544217 KH176 is well tolerated
and displays a promising
PK profile
Khondrion, Nijmegen, the
Netherlands
Idebenone
(a.k.a. Catena®,
Raxone®, Sovrima®)
LHON Phase 2 double-blind,
randomized, placebo-
controlled study of the
efficacy, safety, and
tolerability
NCT00747487 The primary end point
did not reach statistical
significance. In a
subgroup of patients
with discordant visual
acuities at baseline, all
secondary end points
were significantly
different between the
idebenone and placebo
groups
Santhera Pharmaceuticals,
Liestal, Switzerland
FRDA Phase 3 double-blind,
randomized, placebo-
controlled study of the
efficacy, safety, and
tolerability
NCT00537680 Idebenone did not
significantly alter
neurological function
in FRDA during the 6-
month
study
MELAS Phase 2a double-blind,
randomized, placebo-
controlled, dose-finding
study
NCT00887562 No results reported
EPI-743
(a.k.a. Vatiquinone®,
Vincerinone®)
LS Phase 2B randomized,
placebo-controlled, double-
blind clinical trial
NCT01721733 Study status unknown Edison Pharmaceuticals,
Mountain View, USA
FRDA Safety and efficacy study on
visual function
NCT01728064 Ongoing, not
recruiting
MRCD Emergency use protocol for
EPI-743 in acutely ill patients
with inherited MRCD
(90 days of end-of-life care)
NCT01370447 Ongoing, not
recruiting
PS Open-label phase 2 safety
and efficacy study
NCT02104336 Ongoing, not
recruiting
FRDA Phase 2A clinical trial on
visual function in patients
with point mutations
NCT01962363 Ongoing, not recruiting University of South Florida,
Tampa, USA
MTP-131
(a.k.a. Bendavia®)
MM Phase 1/2 multicenter,
randomized, double-blind,
placebo-controlled, multiple
ascending-dose clinical study
investigating the safety,
tolerability, and efficacy of
intravenous MTP-131 for the
treatment of MM in subjects
with genetically confirmed
MD
NCT02367014 Recruiting Stealth BioTherapeutics
Inc., Newton, USA
SMMDE Phase 2 randomized, double-
blind, placebo-controlled
study to evaluate the impact
of a single intravenous
dose
NCT02245620 Recruiting
ª 2016 The Authors EMBO Molecular Medicine Vol 8 | No 4 | 2016
Werner JH Koopman et al Treatment of pediatric OXPHOS disorders EMBO Molecular Medicine
321
Published online: March 7, 2016 
studied alone in a compassionate use program using a single
patient with mitochondrial myopathy, but no results are currently
available.
• RTA408 activates the cytoprotective transcription factor nuclear
factor (erythroid-derived 2)-like 2 (Nrf2, a.k.a. NFE2L2), a master
regulator of cellular antioxidant responses (Reisman et al, 2014).
Table 2 (continued)
Molecule name
Targeted
disease Clinical phase
Clinical trial
identifiera Primary results Sponsor
RP103
(Cysteamine
bitartrate)
Inherited MD
including LS
A phase 2/3 open-label, dose-
escalating study to assess
safety, tolerability, efficacy,
PK, and PD of RP103
delayed-release
capsules in children
NCT02023866
RP103-MITO-
001
Recruiting Raptor pharmaceuticals,
Novato, USA
A phase 2 long-term open-
label extension study of
RP103-MITO-001 to assess
the safety, tolerability and
efficacy of RP103 delayed-
release capsules for
treatment of children
NCT02473445 Recruiting
Coenzyme Q10 Children inherited
MD due to defects
in specific ETC
complexes or
mtDNA mutations
Phase 3 trial NCT00432744 Completed. No results
reported yet
University of Florida; FDA
office of orphan products
development, USA
Bezafibrate MD
(Confirmed
mt.3243A>G
mutation)
Open-label phase 2
feasibility study
NCT02398201 Recruiting not started Newcastle-upon-Tyne
Hospitals NHS foundation
Trust, Newcastle, UK
RG2133
(20 ,30 ,50-tri-O-
acetyluridine)
MD Open-label dose-escalation
phase I study to assess the
safety, tolerability, PK, and
PD of RG2133 in treatment of
inherited MD
NCT00060515 Terminated. No results
reported
Repligen Corp, Waltham,
USA
DCA (dichloroacetate) MELAS Phase 2: investigation of
clinical syndromes
associated with mtDNA
point mutations
NCT00068913 Terminated prematurely
because of peripheral
nerve toxicity
Eunice Kennedy Shriver
NICHD, Bethesda, USA
ARG and CIT MELAS Open-label phase 2: ARG flux
and NO production in
patients and the effect of
dietary ARG and CIT
supplementation
NCT01339494 Unknown Baylor College of Medicine,
Houston, USA
ARG MELAS Open-label phase 2 on 3
siblings: Efficacy of L-
arginine therapy on
endothelium-dependent
vasodilation and
mitochondrial metabolism
NCT01603446 Completed. A significant
increase of the
maximum work
performed at anaerobic
threshold was observed
The Hospital for Sick
Children, Ontario, Canada
Lipoic acid
(a.k.a. Thioctic acid)
MM Pilot compassionate use
study
NCT00004770 No results reported National Center for
Research Resources
(NCRR), Bethesda, USA
RTA408 MM Phase 2 study of the safety,
efficacy, and PD of the
Nrf2-activator RTA408
NCT02255422 Recruiting Reata Pharmaceuticals Inc,
Irving, USA
Curcumin LHON Phase 3 randomized, double-
blind, placebo-controlled trial
NCT00528151 No results reported Mahidol University, Salaya,
Thailand
aSource: www.clinicaltrials.gov.
ARG, arginine; CIT, citrulline; ETC, electron transport chain; FDA, Food and Drug Administration; FRDA, Friedreich’s Ataxia; GLC, glucose; LHON, Leber hereditary
optic neuropathy; LS, Leigh syndrome; MD, mitochondrial disease; MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MM,
mitochondrial myopathy; MRCD, mitochondrial respiratory chain diseases; mtDNA, mitochondrial DNA: NICHD, National Institute of Child Health and Human
Development; NO, nitric oxide; Nrf2 (a.k.a. NFE2L2), nuclear factor (erythroid-derived 2)-like 2; PD, pharmacodynamics; PK, pharmacokinetics; PS, Pearson
syndrome; SMMDE, skeletal muscle mitochondrial dysfunction in the elderly.
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This compound has entered clinical trials for the treatment of
mitochondrial myopathy (phase 2) and is reported to stimulate
mitochondrial biogenesis and function (Neymotin et al, 2011),
and increase the expression of cellular antioxidant defense
systems (Saha et al, 2010).
• Curcumin, a biomolecule from the golden spice turmeric
(Curcuma longa), can modulate multiple cell-signaling pathways
and displays antioxidant properties (Gupta et al, 2011; Trujilo
et al, 2014). A randomized and controlled phase 3 study in LHON
patients carrying the G11778A mtDNA, mutation has been
completed but no results have been reported yet.
Various other small-molecule treatments are currently under
investigation but still at the early preclinical stage. For example, a
novel cell-permeable variant of the complex II substrate succinate
(NVP015; Neurovive Pharmaceuticals, Lund, Sweden) has been
generated to allow bypassing of dysfunctional complex I. In
addition, using a mouse model of isolated complex I deficiency
(NDUFS4/ mice; Kruse et al, 2008), positive effects of the mTOR
inhibitor rapamycin (Johnson et al, 2013, 2015), nicotinamide ribo-
side (a natural precursor of NAD+) (Karamanlidis et al, 2013), and
inhibition of poly ADP ribose polymerase (PARP) have been
reported (Felici et al, 2014). Both nicotinamide riboside and PARP
inhibition are thought to improve mitochondrial function by
enhancing intracellular NAD+ levels (Cerutti et al, 2014). Further
potential strategies, including mitochondria-targeted small mole-
cules, have recently been presented elsewhere (e.g., Horobin et al,
2007; Karamanlidis et al, 2013; Apostolova & Victor, 2014; Khan
et al, 2014; Malti et al, 2014; Peralta et al, 2015; Rai et al, 2015;
Viscomi et al, 2015).
Future perspectives
There is an unmet need for development of clinically relevant treat-
ment strategies for children (and adults) suffering from mitochon-
drial disease. Developing such a treatment faces many challenges
including the small number of established diagnostic and prognostic
biomarkers, the lack of truly objective and validated outcome
measures that reflect daily life activities/well-being, and the small
number of homogenous patients. To systematically overcome these
hurdles, (more) international collaboration between mitochondrial
expert centers, patient organizations, industrial partners, and other
stakeholders, as well as sufficient funding options, is essential. The
tasks ahead include the establishment of guidelines for high-quality
studies, and to improve trial design, for instance, by harmonization
of outcome measures.
Acknowledgements
This research was supported by a PM-Rare (Priority Medicines Rare disor-
ders and orphan diseases) grant from the Netherlands Organization for
Health Research and Development-Medical Sciences (No: 40-41900-98-033),
the Stichting Energy4All (www.energy4all.eu), and the CSBR (Centres for
Systems Biology Research) initiative from the Netherlands Organisation for
Scientific Research (NWO; No: CSBR09/013V). The authors express their
gratitude to all RCMM and Khondrion team members. We apologize to
those authors whose articles we were unable to cite because of space
limitations.
Conflict of interest
JAMS is the founding CEO of Khondrion (www.khondrion.com), a Radboud
University Medical Center spin-off biotech company. JB is the COO, and
PHGMW and WJHK are scientific consultants of this company.
References
Alam NM, Mills WC 4th, Wong AA, Douglas RM, Szeto HH, Prusky GT (2015)
A mitochondrial therapeutic reverses visual decline in mouse models of
diabetes. Dis Model Mech 8: 701 – 710
Alfano LN, Lowes LP, Berry KM, Yin H, Dvorchik I, Flanigan KM, Cripe L,
Mendell JR (2014) P.1: Pilot study evaluating motivation on the
performance of timed walking in boys with Duchenne muscular
dystrophy. Neuromuscul Disord 24: 860
Apostolova N, Victor VM (2014) Molecular strategies for targeting
antioxidants to mitochondria: therapeutic implications. Antioxid Redox
Signal 22: 686 – 729
Augustine EF, Adams HR, Mink JW (2013) Clinical trials in rare disease:
challenges and opportunities. J Child Neurol 28: 1142 – 1150
Balke B (1963) A simple field test for the assessment of physical fitness. Rep
Civ Aeromed Res Inst US 1 – 8
Barth PG, Scholte HR, Berden JA, Van der Klei-Van Moorsel JM, Luyt-Houwen
IE, Van‘t Veer-Korthof ET, Van der Harten JJ, Sobotka-Plojhar MA (1983) An
X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle
and neutrophil leucocytes. J Neurol Sci 62: 327 – 355
Bernier FP, Boheh A, Dennet X, Chow CW, Cleary MA, Thorburn DR (2002)
Diagnostic criteria for respiratory chain disorders in adults and children.
Neurology 59: 1406 – 1411
Berry DA (2006) Bayesian clinical trials. Nat Rev Drug Discov 5: 27 – 36
Besouw M, Tangerman A, Cornelissen E, Rioux P, Levtchenko E (2012)
Halitosis in cystinosis patients after administration of immediate-release
cysteamine bitartrate compared to delayed-release cysteamine bitartrate.
Mol Genet Metab 107: 234 – 236
Pending issues
(i) Outcome measures: The validation and harmonization of objective
clinically relevant outcome measures in children with mitochon-
drial disease is a crucial step in the interpretation of drug
effectiveness. This requires an active stimulation of patient partic-
ipation and warrants further international collaboration. The
same holds true for diagnostic biomarkers suited for use during
intervention studies and prognosis.
(ii) Natural history studies: Due to the relatively limited number of
pediatric patients in which a genetic defect is firmly established,
international initiatives are required for proper intervention test-
ing.
(iii) Clinical trials: Although many different designs of clinical trials
exist, their results should be carefully interpreted and include
clinical relevant primary endpoints. The latter are dictated by the
available population of affected patients.
(iv) Genotype–phenotype relationship: It is unclear why mutations in
different genes are associated with similar clinical phenotypes
and why similar mutations are associated with different pheno-
types. Moreover, it is unknown why certain mutations display
tissue-specific effects. Environmental and/or patient-specific
factors might explain such differences and therefore require
further exploration.
ª 2016 The Authors EMBO Molecular Medicine Vol 8 | No 4 | 2016
Werner JH Koopman et al Treatment of pediatric OXPHOS disorders EMBO Molecular Medicine
323
Published online: March 7, 2016 
Blanchet L, Buydens MC, Smeitink JAM, Willems PHGM, Koopman WJH (2011)
Isolated mitochondrial complex I deficiency: explorative data analysis of
patient cell parameters. Curr Pharm Des 17: 4023 – 4033
Blanchet L, Smeitink JAM, van Emst-de Vries SE, Vogels C, Pellegrini M,
Jonckheere AI, Rodenburg RJ, Buydens LM, Beyrath J, Willems PHGM
et al (2015) Quantifying small molecule phenotypic effects using
mitochondrial morpho-functional fingerprinting and machine learning.
Sci Rep 5: 8035
Blessberger H, Binder T (2010) Two dimensional speckle tracking
echocardiography: basic principles. Heart 96: 716 – 722
van Bon BW, Oortveld MA, Nijtmans LG, Fenckova M, Nijhof B, Besseling J,
Vos M, Kramer JM, de Leeuw N, Castells-Nobau A et al (2013) CEP89 is
required for mitochondrial metabolism and neuronal function in man and
fly. Hum Mol Gen 22: 3138 – 3151
Bouabe H, Fässler R, Heesemann J (2008) Improvement of reporter activity by
IRES-mediated polycistronic reporter system. Nucl Acids Res 36: e28
Brunner HI, Ravelli A (2009) loping outcome measures for paediatric
rheumatic diseases. Best Pract Res Clin Rheumatol 23: 609 – 624
Casey AF, Wang X, Osterling K (2012) Test-retest reliability of the 6-minute
walk test in individuals with Down syndrome. Arch Phys Med Rehabil 93:
2068 – 2074
Cerutti R, Pirinen E, Lamperti C, Marchet S, Sauve AA, Li W, Leoni V, Schon
EA, Dantzer F, Auwerx J et al (2014) NAD-dependent activation of Sirt1
corrects the phenotype in a mouse model of mitochondrial disease. Cell
Metab 19: 1042 – 1049
Chinnery PF (2015) Mitochondrial disease in adults: what’s old and what’s
new. EMBO Mol Med 7: 1503 – 1512
Chow SC, Chang M (2008) Adaptive design methods in clinical trials - a
review. Orphanet J Rare Dis 3: 11
Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, Rosati A, Pons G,
Tiddens H, Chabaud S, Aarons L, Bajard A, Ballot C, Bertrand Y, Bretz F,
Caudri D, Castellan C, Chabaud S, Cornu C, Dufour F, Dunger-Baldauf C,
Dupont JM, Fisch R, Guerrini R, Jullien V, Kassaï B, Nony P, Ogungbenro K,
Pérol D, Pons G, Tiddens H, Rosati A, Alberti C, Chiron C, Kurbatova P,
Nabbout R (2013) Experimental designs for small randomised clinical
trials: an algorithm for choice. Orphanet J Rare Dis 8: 48
DaRe JT, Vasta V, Penn J, Tran NT, Hahn SH (2013) Targeted exome
sequencing for mitochondrial disorders reveals high genetic heterogeneity.
BMC Med Genet 14: 118
Daud D, Griffin H, Douroudis K, Kleinle S, Eglon G, Pyle A, Chinnery PF,
Horvath R (2015) Whole exome sequencing and the clinician: we need
clinical skills and functional validation in variant filtering. J Neurol 262:
1673 – 1677
Dirks I, Koene S, Verbruggen R, Smeitink JAM, Jansen M, de Groot IJM (2015)
The assisted 6-minute cycling test: An exploratory study in children.
Muscle Nerve doi: 10.1002/mus.25021
Distelmaier F, Visch HJ, Smeitink JA, Mayatepek E, Koopman WJH, Willems
PHGM (2009) The antioxidant Trolox restores mitochondrial membrane
potential and Ca2+-stimulated ATP production in human complex I
deficiency. J Mol Med 87: 515 – 522
Distelmaier F, Valsecchi F, Forkink M, van Emst-de Vries S, Swarts HG,
Rodenburg RJ, Verwiel ET, Smeitink JA, Willems PHGM, Koopman WJH
(2012) Trolox-sensitive reactive oxygen species regulate mitochondrial
morphology, oxidative phosphorylation and cytosolic calcium handling in
healthy cells. Antioxid Redox Signal 17: 1657 – 1669
Distelmaier F, Valsecchi F, Liemburg-Apers DC, Lebiedzinska M, Rodenburg RJ,
Heil S, Keijer J, Fransen J, Imamura H, Danhauser K et al (2015)
Mitochondrial dysfunction in primary human fibroblasts triggers an
adaptive cell survival program that requires AMPK-a. Biochim Biophys Acta
1852: 529 – 540
Dubrovsky A, Chloca F, Corderi JR, Jauregui A (2013) P.17.3 Changes in the
six minute walk test (6MWT) in Pompe disease. Neuromuscul Disord 23:
827
Enns GM, Kinsman SL, Perlman SL, Spicer KM, Abdenur JE, Cohen BH,
Amagata A, Barnes A, Kheifets V, Shrader WD et al (2012) Initial
experience in the treatment of inherited mitochondrial disease with EPI-
743. Mol Genet Metab 105: 91 – 102
Etzioni R, Gulati R, Lin DW (2015) Measures of survival benefit in cancer drug
development and their limitations. Urol Oncol 33: 122 – 127
Felici R, Cavone L, Lapucci A, Guasti D, Bani D, Chiarugi A (2014) PARP
inhibition delays progression of mitochondrial encephalopathy in mice.
Neurotherapeutics 11: 651 – 664
Fernandez-Martos C, Guerrero A, Minsky B (2012) Clinically relevant
study end points in rectal cancer. Recent Results Cancer Res 196:
3 – 19
Forkink M, Manjeri GR, Liemburg-Apers DC, Nibbeling E, Blanchard M,
Wojtala A, Smeitink JAM, Wieckowski MR, Willems PHGM, Koopman WJH
(2014) Mitochondrial hyperpolarization during chronic complex I
inhibition is sustained by low activity of complex II, III, IV and V. Biochim
Biophys Acta 1837: 1247 – 1256
Forkink M, Basit F, Teixeira J, Swarts HG, Koopman WJH, Willems PHGM
(2015) Complex I and complex III inhibition specifically increase cytosolic
hydrogen peroxide levels without inducing oxidative stress in HEK293
cells. Redox Biol 6: 607 – 616
Friedman LS, Farmer JM, Perlman S, Wilmot G, Gomez CM, Bushara KO,
Mathews KD, Subramony SH, Ashizawa T, Balcer LJ et al (2010) Measuring
the rate of progression in Friedreich ataxia: implications for clinical trial
design. Mov Disord 25: 426 – 432
Giorgio V, Petronilli V, Ghelli A, Carelli V, Rugolo M, Lenaz G, Bernardi P
(2011) The effects of idebenone on mitochondrial bioenergetics. Biochim
Biophys Acta 1817: 363 – 369
Glover EI, Martin J, Maher A, Thornhill RE, Moran GR, Tarnopolsky MA (2010)
A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle
Nerve 42: 739
Golubitzky A, Phyllis D, Weismann S, Link G, Wikstrom JD, Saada A (2011)
Screening for active small molecules in mitochondrial complex I deficient
patient’s fibroblasts, reveals AICAR as the most beneficial compound. PLoS
One 6: e26883
Grady JP, Campbell G, Ratnaike T, Blakely EL, Falkous G, Nesbitt V, Schaefer
AM, McNally RJ, Gorman GS, Taylor RW et al (2014) Disease progression in
patients with single, large-scale mitochondrial DNA deletions. Brain 137:
323 – 334
Gupta D, Lammersfeld CA, Vashi PG, King J, Dahlk SL, Grutsch JF, Lis CG
(2009) Bioelectrical impedance phase angle in clinical practice:
implications for prognosis in stage IIIB and IV non-small cell lung cancer.
BMC Cancer 9: 37
Gupta SC, Patchva S, Aggarwal BB (2011) Therapeutic roles of curcumin:
lessons learned from clinical trials. AAPS J 15: 195 – 218
Haack TB, Haberberger B, Frisch EM, Wieland T, Iuso A, Gorza M, Strecker V,
Graf E, Mayr JA, Herberg U et al (2012) Molecular diagnosis in
mitochondrial complex I deficiency using exome sequencing. J Med Genet
49: 277 – 283
Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier Fruh I, Anklin C,
Dallmann R, Gueven N (2011) NQO1-dependent redox cycling of
idebenone: effects on cellular redox potential and energy levels. PLoS
One 6: e17963
EMBO Molecular Medicine Vol 8 | No 4 | 2016 ª 2016 The Authors
EMBO Molecular Medicine Treatment of pediatric OXPHOS disorders Werner JH Koopman et al
324
Published online: March 7, 2016 
Heeman B, Van den Haute C, Aelvoet SA, Valsecchi F, Rodenburg RJ, Reumers
V, Debyser Z, Callewaert G, Koopman WJH, Willems PHGM et al (2011)
Depletion of PINK1 affects mitochondrial metabolism, calcium
homeostasis and energy maintenance. J Cell Sci 124: 1115 – 1125
Hoefs SJ, Dieteren CE, Distelmaier F, Janssen RJ, Epplen A, Swarts HG,
Forkink M, Rodenburg RJ, Nijtmans LG, Willems PH et al (2008) NDUFA2
complex I mutation leads to Leigh disease. Am J Hum Genet 82:
1306 – 1315
Hoffmann M, Honnen S, Mayatepek E, Wätjen W, Koopman WJH, Bossinger
O, Distelmaier F (2012) MICS-1 interacts with mitochondrial ATAD-3 and
modulates lifespan in C elegans. Exp Gerontol 47: 270 – 275
Horobin RW, Trapp S, Weissig V (2007) Mitochondriotropics: a review of their
mode of action, and their applications for drug and DNA delivery to
mammalian mitochondria. J Contr Rel 121: 125 – 136
Jaber S, Polster BM (2015) Idebenone and neuroprotection: antioxidant, pro-
oxidant, or electron carrier? J Bioenerg Biomembr 47: 111 – 118
Jefferies JL (2013) Barth syndrome. Am J Med Genet C Semin Med Genet 163C:
198 – 205
Jiang D, Li J, Xiao X, Li S, Jia X, Sun W, Guo X, Zhang Q (2014) Detection of
mutations in LRPAP1, CTSH, LEPREL1, ZNF644, SLC39A5, and SCO2 in 298
families with early-onset high myopia by exome sequencing. Invest
Ophthalmol Vis Sci 56: 339 – 345
Johnson SC, Yanos ME, Kayser EB, Quintana A, Sangesland M, Castanza A,
Uhde L, Hui J, Wall VZ, Gagnidze A et al (2013) mTOR inhibition alleviates
mitochondrial disease in a mouse model of Leigh syndrome. Science 342:
1524 – 1528
Johnson SC, Yanos ME, Bitto A, Castanza A, Gagnidze A, Gonzalez B, Gupta K,
Hui J, Jarvie C, Johnson BM et al (2015) Dose-dependent effects of mTOR
inhibition on weight and mitochondrial disease in mice. Front Genet 22: 247
Jonckheere AI, Huigsloot M, Lammens M, Jansen J, van den Heuvel LP,
Spiekerkoetter U, von Kleist-Retzow JC, Forkink M, Koopman WJ,
Szklarczyk R et al (2011) Restoration of complex V deficiency caused by a
novel deletion in the human TMEM70 gene normalizes mitochondrial
morphology. Mitochondrion 11: 954 – 963
Jonckheere AI, Renkema GH, Bras M, van den Heuvel LP, Hoischen A, Gilissen
C, Nabuurs SB, Huynen MA, de Vries MC, Smeitink JA et al (2013) A
complex V ATP5A1 defect causes fatal neonatal mitochondrial
encephalopathy. Brain 136: 1544 – 1554
Kang PB (2013) Beyond the gowers sign: measuring outcomes in Duchenne
muscular dystrophy. Muscle Nerve 48: 315 – 317
Karamanlidis G, Lee CF, Garcia-Menendez L, Kolwicz SC Jr, Suthammarak W,
Gong G, Sendensky MM, Morgan PG, Wang W, Tian R (2013)
Mitochondrial complex I deficiency increases protein acetylation and
accelerates heart failure. Cell Metab 18: 239 – 250
Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, Shungu DC, Millar WS,
Hong X, Gooch CL, Mao X et al (2006) Dichloroacetate causes toxic
neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 66:
324 – 330
Kerr DS (2013) Review of clinical trials for mitochondrial disorders: 1997-2012.
Neurotherapeutics 10: 307 – 319
Khan NA, Auranen M, Paetau I, Pirinen E, Euro L, Forsstrom S, Pasila L,
Velagapudi V, Carroll CJ, Auwerx J et al (2014) Effective treatment of
mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO
Mol Med 6: 721 – 731
Kirby DM, Salemi R, Sugiana C, Othake A, Parry L, Bell KM, Kirk EP, Boneh
A, Taylor RW, Dahl HH et al (2004) NDUFS6 mutations are a novel
cause of neonatal mitochondrial complex I deficiency. J Clin Invest 114:
83 – 845
Kisler JE, Whittaker RG, McFarland R (2010) Mitochondrial diseases in
childhood: a clinical approach to investigation and management. Dev Med
Child Neurol 52: 422 – 433
Koene S, de Laat P, van Tienoven DH, Vriens D, Brandt AM, Sweep FC,
Rodenburg RJ, Donders AR, Janssen MC, Smeitink JAM (2014) Serum FGF21
levels in adult m.3243A>G carriers: clinical implications. Neurology 83:
125 – 133
Koene S, de Laat P, van Tienoven DH, Weijers G, Vriens D, Sweep FC,
Timmermans J, Kapusta L, Janssen MC, Smeitink JAM (2015) Serum GDF15
levels correlate to mitochondrial disease severity and myocardial strain,
but not to disease progression in adult m.3243A>G carriers. JIMD Rep 24:
69 – 81
Koene S, Wortmann SB, de Vries MC, Jonckheere AI, Morava E, de Groot IJ,
Smeitink JA (2013a) Developing outcome measures for pediatric
mitochondrial disorders: which complaints and limitations are most
burdensome to patients and their parents? Mitochondrion 13: 15 – 24
Koene S, Jansen M, Verhaak CM, De Vrueh RL, De Groot IJ, Smeitink JAM
(2013b) Towards the harmonization of outcome measures in children with
mitochondrial disorders. Dev Med Child Neurol 55: 698 – 706
Koene S, Smeitink JAM (2011) Mitochondrial Medicine, a clinical guideline,
ISBN 978-90-817737-0-6
Koopman WJH, Visch HJ, Verkaart S, van den Heuvel LW, Smeitink JAM,
Willems PHGM (2005) Mitochondrial network complexity and
pathological decrease in complex I activity are tightly correlated in
isolated human complex I deficiency. Am J Physiol Cell Physiol 289:
C881 –C890
Koopman WJH, Verkaart S, Visch HJ, van Emst-de Vries S, Nijtmans LG,
Smeitink JAM, Willems PHGM (2007) Human NADH: ubiquinone
oxidoreductase deficiency: radical changes in mitochondrial morphology?
Am J Physiol Cell Physiol 293: C22 –C29
Koopman WJH, Verkaart S, van Emst-de Vries SE, Grefte S, Smeitink JAM,
Nijtmans LG, Willems PHGM (2008) Mitigation of NADH: ubiquinone
oxidoreductase deficiency by chronic Trolox treatment. Biochim Biophys
Acta 1777: 853 – 859
Koopman WJH, Nijtmans LG, Dieteren CE, Roestenberg P, Valsecchi F,
Smeitink JA, Willems PHGM (2010) Mammalian mitochondrial complex I:
biogenesis, regulation, and reactive oxygen species generation. Antioxid
Redox Signal 12: 1431 – 1470
Koopman WJH, Willem PHGM, Smeitink JAM (2012) Monogenic mitochondrial
disorders. N Engl J Med 366: 1132 – 1141
Koopman WJH, Distelmaier F, Smeitink JAM, Willems PHGM (2013) OXPHOS
mutations and neurodegeneration. EMBO J 32: 9 – 29
Koufaki M (2014) Therapeutic applications of lipoic acid: a patent review
(2011-2014). Expert Opin Ther Pat 24: 993 – 1005
Kruse SE, Watt WC, Marcinek DJ, Kapur RP, Schenkman KA, Palmiter RD
(2008) Mice with mitochondrial complex I deficiency develop a fatal
encephalomyopathy. Cell Metab 7: 312 – 320
Lake NJ, Compton AG, Rahman S, Thorburn DR (2016) Leigh Syndrome: one
disorder, more than 75 monogenic causes. Ann Neurol 79: 190 – 203
Lee SK, Kim J, Kim HD, Lee JS, Lee YM (2010) Initial experiences with proton
MR spectroscopy in treatment monitoring of mitochondrial
encephalopathy. Yonsei Med J 51: 672 – 675
Leman G, Gueguen N, Desquiret-Dumas V, Kane MS, Wettervald C, Chupin S,
Chevrollier A, Lebre AS, Bonnefont JP, Barth M et al (2015) Assembly
defects induce oxidative stress in inherited mitochondrial complex I
deficiency. Int J Biochem Cell Biol 65: 91 – 103
Lieber DS, Calvo SE, Shanahan K, Slate NG, Liu S, Hershman SG, Gold NB,
Chapman BA, Thorburn DR, Berry GT et al (2013) Targeted exome
ª 2016 The Authors EMBO Molecular Medicine Vol 8 | No 4 | 2016
Werner JH Koopman et al Treatment of pediatric OXPHOS disorders EMBO Molecular Medicine
325
Published online: March 7, 2016 
sequencing of suspected mitochondrial disorders. Neurology 80:
1762 – 1770
Liemburg-Apers DC, Imamura H, Forkink M, Nooteboom M, Swarts HG,
Brock R, Smeitink JAM, Willems PHGM, Koopman WJH (2011)
Quantitative glucose and ATP sensing in mammalian cells. Pharm Res 28:
2745 – 2757
Liemburg-Apers DC, Schirris TJ, Russel FG, Willems PHGM, Koopman WJH
(2015) Mitoenergetic dysfunction triggers a rapid compensatory increase
in steady-State glucose flux. Biophys J 109: 1372 – 1386
Lightowlers RN, Taylor RW, Turnbull DM (2015) Mutations causing
mitochondrial disease: what is new and what challenges remain? Science
349: 1494 – 1499
Luft R, Ikkos D, Palmieri G, Ernster L, Afzelius B (1962) A case of severe
hypermetabolism of nonthyroid origin with a defect in the maintenance
of mitochondrial respiratory control: a correlated clinical, biochemical, and
morphological study. J Clin Invest 41: 1776 – 1804
Malti RH, Jessulat M, Jin K, Musso G, Vlasblom J, Phanse S, Zhang Z, Babu M
(2014) Mitochondrial targets for pharmacological intervention in human
disease. J Prot Res 14: 5 – 21
Martinelli D, Catteruccia M, Piemonte F, Pastore A, Tozzi G, Dionisi-Vici C,
Pontrelli G, Corsetti T, Livadiotti S, Kheifets V et al (2012) EPI-743 reverses
the progression of the pediatric mitochondrial disease-genetically defined
Leigh Syndrome. Mol Genet Metab 107: 383 – 388
Mayr JA, Haack TB, Freisinger P, Karall D, Makowski C, Koch J, Feichtinger RG,
Zimmermann FA, Rolinski B, Ahting U et al (2015) Spectrum of combined
respiratory chain defects. J Inherit Metab Dis 38: 629 – 640
Mitchell P (1961) Coupling of phosphorylation to electron and hydrogen
transfer by a chemi-osmotic type of mechanism. Nature 191: 144 – 148
Mortiboys H, Thomas KJ, Koopman WJH, Klaffke S, Abou-Sleiman P, Olpin S,
Wood NW, Willems PHGM, Smeitink JAM, Cookson MR et al (2008)
Mitochondrial function and morphology are impaired in parkin-mutant
fibroblasts. Ann Neurol 64: 555 – 565
Nesbitt V, McFarland R (2011) Phenotypic spectrum of m.3243A>G
mitochondrial DNA mutation in children. Arch Dis Child 96: A28
Neymotin A, Calingasan N, Wile E (2011) Neuroprotective effect of Nrf2/ARE
activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse
model of amyotrophic lateral sclerosis. Free Rad Biol Med 51: 88 – 96
Ngu LH, Nijtmans LG, Distelmaier F, Venselaar H, van Emst-de Vries SE, van
den Brand MA, Stoltenborg BJ, Wintjes LT, Willems PH, van den Heuvel LP
et al (2012) A catalytic defect in mitochondrial respiratory chain complex I
due to a mutation in NDUFS2 in a patient with Leigh syndrome. Biochim
Biophys Acta 1822: 168 – 175
Nouws J, Nijtmans LG, Smeitink JAM, Vogel RO (2012) Assembly factors as a
new class of disease genes for mitochondrial complex I deficiency: cause,
pathology and treatment options. Brain 135: 12 – 22
Ohtake A, Murayama K, Mori M, Harashima H, Yamazaki T, Tamaru S,
Yamashita Y, Kishita Y, Nakachi Y, Kohda M et al (2014) Diagnosis and
molecular basis of mitochondrial respiratory chain disorders: exome
sequencing for disease gene identification. Biochim Biophys Acta 1840:
1355 – 1359
Ostergaard E, Weraarpachai W, Ravn K, Born AP, Jonson L, Duno M, Wibrand
F, Shoubridge EA, Vissing J (2015) Mutations in COA3 cause isolated
complex IV deficiency associated with neuropathy, exercise intolerance,
obesity, and short stature. J Med Genet 52: 203 – 207
Palmieri F (2008) Diseases caused by defects of mitochondrial carriers: a
review. Biochim Biophys Acta 1777: 564 – 578
Pastore A, Petrillo S, Tozzi G, Carrozzo R, Martinelli D, Dionisi-Vici C, Di
Giovamberardino G, Ceravolo F, Klein MB, Miller G et al (2013)
Glutathione: a redox signature in monitoring EPI-743 therapy in children
with mitochondrial encephalomyopathies. Mol Genet Metab 109: 208 – 214
Peralta S, Torraco A, Iommarini L, Diaz F (2015) Mitochondrial diseases part
III: therapeutic interventions in mouse models of oxphos deficiencies.
Mitochondrion 23: 71 – 80
Pfeffer G, Horvath R, Klopstock T, Mootha VK, Suomalainen A, Koene S, Hirano
M, Zeviani M, Bindoff LA, Yu-Wai-Man P et al (2013) New treatments for
mitochondrial disease-no time to drop our standards. Nat Rev Neurol 9:
474 – 481
Picard M, Taivassalo T, Ritchie D, Wright KJ, Thomas MM, Romestaing C,
Hepple RT (2011) Mitochondrial structure and function are disrupted by
standard isolation methods. PLoS One 6: e18317
Preiss D, Sattar N, McMurray JJ (2011) A systematic review of event rates in
clinical trials in diabetes mellitus: the importance of quantifying baseline
cardiovascular disease history and proteinuria and implications for clinical
trial design. Am Heart J 161: 210 – 219
Pritchard JF, Jurima-Romet M, Reimer MLJ, Mortimer E, Rolfe B, Cayen MN
(2003) making better drugs: decision gates in non-clinical drug
development. Nat Rev Drug Discov 2: 542 – 553
van Rahden VA, Fernandez-Vizarra E, Alawi M, Brand K, Fellmann F, Horn D,
Zeviani M, Kutsche K (2015) Mutations in NDUFB11, encoding a complex I
component of the mitochondrial respiratory chain, cause microphthalmia
with linear skin defects syndrome. Am J Hum Genet 96: 640 – 650
Rai PK, Russell OM, Lightowlers RN, Turnbull DM (2015) Potential compounds
for the treatment of mitochondrial disease. Br Med Bull 116: 5 – 18
Reisman SA, Lee CY, Meyer CJ, Proksch JW, Ward KW (2014) Topical
application of the synthetic triterpenoid RTA 408 activates Nrf2 and
induces cytoprotective genes in rat skin. Arch Dermatol Res 306:
447 – 454
Rigaud C, Rigaud C, Lebre AS, Touraine R, Beaupain B, Ottolenghi C, Chabli A,
Ansquer H, Ozsahin H, Di FS et al (2013) Natural history of Barth syndrome:
a national cohort study of 22 patients. Orphanet J Rare Dis 8: 70
Roberts AE, Nixon C, Steward CG, Gauvreau K, Maisenbacher M, Fletcher M,
Geva J, Byrne BJ, Spencer CT (2012) The Barth Syndrome Registry:
distinguishing disease characteristics and growth data from a longitudinal
study. Am J Med Genet A 158A: 2726 – 2732
Rodan LH, Wells GD, Banks L, Thompson S, Schneiderman JE, Tein I (2015) L-
Arginine Affects Aerobic Capacity and Muscle Metabolism in MELAS
(Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like
Episodes) Syndrome. PLoS One 10: e0127066
Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky
MA (2007) Beneficial effects of creatine, CoQ10, and lipoic acid in
mitochondrial disorders. Muscle Nerve 35: 235 – 242
Roestenberg P, Manjeri GR, Valsecchi F, Smeitink JAM, Willems PHGM,
Koopman WJH (2012) Pharmacological targeting of mitochondrial complex
I deficiency: the cellular level and beyond. Mitochondrion 12: 57 – 65
Sadun AA, Chicani CF, Ross-Cisneros FN, Barboni P, Thoolen M, Shrader WD,
Kubis K, Carelli V, Miller G (2012) Effect of EPI-743 on the clinical course
of the mitochondrial disease Leber hereditary optic neuropathy. Arch
Neurol 69: 331 – 338
Saha P, Reddy V, Knopleva M (2010) The triterpenoid 2-cyano-3,12-
dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic
effects in diet-induced diabetic mice and Lepr(db/db) mice. J Biol Chem
285: 40581 – 40592
Schirris TJ, Renkema GH, Ritschel T, Voermans NC, Bilos A, van Engelen BG,
Brandt U, Koopman WJH, Beyrath JD, Rodenburg RJ et al (2015) Statin-
induced myopathy is associated with mitochondrial complex III inhibition.
Cell Metab 22: 399 – 407
EMBO Molecular Medicine Vol 8 | No 4 | 2016 ª 2016 The Authors
EMBO Molecular Medicine Treatment of pediatric OXPHOS disorders Werner JH Koopman et al
326
Published online: March 7, 2016 
Schöckel L, Glasauer A, Basit F, Bitschar K, Truong H, Erdmann G, Algire C,
Hägebarth A, Willems PHGM, Kopitz C et al (2015) Targeting
mitochondrial complex I using BAY 87-2243 reduces melanoma tumor
growth. Cancer Metab 3: 11
Schwab MA, Sauer SW, Okun JG, Nijtmans LG, Rodenburg RJ, van den Heuvel
LP, Dröse S, Brandt U, Hoffmann GF, Ter Laak H et al (2006) Secondary
mitochondrial dysfunction in propionic aciduria: a pathogenic role for
endogenous mitochondrial toxins. Biochem J 398: 107 – 112
Smeitink JAM (2003) Mitochondrial disorders: clinical presentation and
diagnostic dilemmas. J Inherit Metab Dis 26: 199 – 207
Smeitink JAM, van den Heuvel LWPJ, Koopman WJH, Nijtmans LGJ, Ugalde C,
Willems PHGM (2004) Cell biological consequences of mitochondrial NADH:
ubiquinone oxidoreductase deficiency. Curr Neurovasc Res 1: 29 – 40
Spencer CT, Bryant RM, Day J, Gonzalez IL, Colan SD, Thompson WR, Berthy J,
Redfearn SP, Byrne BJ (2006) Cardiac and clinical phenotype in Barth
syndrome. Pediatrics 118: e337 – e346
Stacpoole PW, deGrauw TJ, Feigenbaum AS, Hoppel C, Kerr DS, McCandless
SE, Miles MV, Robinson BH, Tang PH (2012) Design and implementation of
the first randomized controlled trial of coenzyme Q10 in children with
primary mitochondrial diseases. Mitochondrion 12: 623 – 629
Suomalainen A, Elo JM, Pietiläinen KH, Hakonen AH, Sevastianova K, Korpela
M, Isohanni P, Marjavaara SK, Tyni T, Kiuru-Enari S et al (2011) FGF-21 as
a biomarker for muscle-manifesting mitochondrial respiratory chain
deficiencies: a diagnostic study. Lancet Neurol 10: 806 – 818
Szabo I, Zoratti M (2014) Mitochondrial channels: ion fluxes and more.
Physiol Rev 94: 519 – 608
Szeto HH (2014) First-in-class cardiolipin-protective compound as a
therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol
171: 2029 – 2050
Szklarczyk R, Wanschers BF, Nijtmans LG, Rodenburg RJ, Zschocke J, Dikow N,
van den Brand MA, Hendriks-Franssen MG, Gilissen C, Veltman JA et al
(2013) A mutation in the FAM36A gene, the human ortholog of COX20,
impairs cytochrome c oxidase assembly and is associated with ataxia and
muscle hypotonia. Hum Mol Genet 22: 656 – 667
Taylor RW, Pyle A, Griffin H, Blakely EL, Duff J, He L, Smertenko T, Alston CL,
Neeve VC, Best A et al (2014) Use of whole-exome sequencing to
determine the genetic basis of multiple mitochondrial respiratory chain
complex deficiencies. JAMA 312: 68 – 77
Triepels RH, van den Heuvel LP, Loeffen JL, Buskens CA, Smeets RJ, Rubio
Gozalbo ME, Budde SM, Mariman EC, Wijburg FA, Barth PG et al (1999)
Leigh syndrome associated with a mutation in the NDUFS7 (PSST) nuclear
encoded subunit of complex I. Ann Neurol 45: 787 – 790
Trujilo J, Granados-Castro LF, Zazueta C, Andérica-Romero AC, Chirino YI,
Pedraza-Chaverrí J (2014) Mitochondria as a target in the therapeutic
properties of curcumin. Arch Pharm (Weinheim) 347: 873 – 884
Tugwell P, Boers M (1993) OMERACT conference on outcome measures in
rheumatoid arthritis clinical trials: introduction. J Rheumatol 20: 528 – 530
Vafai SB, Mootha VK (2012) Mitochondrial disorders as windows into an
ancient organelle. Nature 491: 374 – 383
Verkaart S, Koopman WJH, van Emst-de Vries SE, Nijtmans LG, van den
Heuvel LW, Smeitink JAM, Willems PHGM (2007a) Superoxide production
is inversely related to complex I activity in inherited complex I deficiency.
Biochim Biophys Acta 1772: 373 – 381
Verkaart S, Koopman WJH, Cheek J, van Emst-de Vries SE, van den Heuvel
LW, Smeitink JAM, Willems PHGM (2007b) Mitochondrial and cytosolic
thiol redox state are not detectably altered in isolated human NADH:
ubiquinone oxidoreductase deficiency. Biochim Biophys Acta 1772:
1041 – 1051
Valsecchi F, Koopman WJH, Manjeri GR, Rodenburg RJ, Smeitink JAM, Willems
PHGM (2010) Complex I disorders: causes, mechanisms, and development
of treatment strategies at the cellular level. Dev Disabil Res Rev 16:
175 – 182
Valsecchi F, Monge C, Forkink M, de Groof AJ, Benard G, Rossignol R, Swarts
HG, van Emst-de Vries SE, Rodenburg RJ, Calvaruso MA et al (2012)
Metabolic consequences of NDUFS4 gene deletion in immortalized mouse
embryonic fibroblasts. Biochim Biophys Acta 1817: 1925 – 1936
Valsecchi F, Grefte S, Roestenberg P, Joosten-Wagenaars J, Smeitink JAM,
Willems PHGM, Koopman WJH (2013) Primary fibroblasts of NDUFS4(-/-)
mice display increased ROS levels and aberrant mitochondrial
morphology. Mitochondrion 13: 436 – 443
Viscomi C, Bottani E, Civiletto G, Cerutti R, Moggio M, Fagiolari G, Schon EA,
Lamperti C, Zeviani M (2011) In vivo correction of COX deficiency by
activation of the AMPK/PGC-1a axis. Cell Metab 14: 80 – 90
Viscomi C, Bottani E, Zeviani M (2015) Emerging concepts in the therapy of
mitochondrial disease. Biochim Biophys Acta 1847: 544 – 557
Wenz T, Diaz F, Spiegelman BM, Moraes CT (2008) Activation of the PPAR/
PGC-1a pathway prevents a bioenergetic deficit and effectively improves a
mitochondrial myopathy phenotype. Cell Metab 8: 249 – 256
Willems PHGM, Wanschers BF, Esseling J, Szklarczyk R, Kudla U, Duarte I,
Forkink M, Nooteboom M, Swarts H, Gloerich J et al (2013) BOLA1 is an
aerobic protein that prevents mitochondrial morphology changes induced
by glutathione depletion. Antioxid Redox Signal 18: 129 – 138
Willems PHGM, Rossignol R, Dieteren CE, Murphy MP, Koopman WJH (2015)
Redox homeostasis and mitochondrial dynamics. Cell Metab 22:
207 – 288
Wolf NI, Smeitink JAM (2002) Mitochondrial disorders: a proposal for
consensus diagnostic criteria in infants and children. Neurology 59:
1402 – 1405
Wortmann SB, Koolen DA, Smeitink JA, van den Heuvel L, Rodenburg RJ
(2015) Whole exome sequencing of suspected mitochondrial patients in
clinical practice. J Inherit Metab Dis 38: 437 – 443
Yamashita S, Nishino I, Nonaka I, Goto Y (2008) Genotype and phenotype
analyses in 136 patients with single large-scale mitochondrial DNA
deletions. J Hum Genet 53: 598 – 606
Yatsuga S, Suomalainen A (2012) Effect of bezafibrate treatment on late-
onset mitochondrial myopathy in mice. Hum Mol Genet 21: 526 – 535
Yatsuga S, Fujita Y, Ishii A, Fukumoto Y, Arahata H, Kakuma T, Kojima T,
Ito M, Tanaka M, Saiki R et al (2015) Growth differentiation factor 15
as a useful biomarker for mitochondrial disorders. Ann Neurol 78:
814 – 823
License: This is an open access article under the
terms of the Creative Commons Attribution 4.0
License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is
properly cited.
ª 2016 The Authors EMBO Molecular Medicine Vol 8 | No 4 | 2016
Werner JH Koopman et al Treatment of pediatric OXPHOS disorders EMBO Molecular Medicine
327
Published online: March 7, 2016 
